Dosage regimen for sotorasib / carboplatin / pemetrexed in cancer treatment
Patent Information
- Application Number
- HK62026126907
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-16
- Filing Date
- 2026-07-31
- Publication Date
- 2026-09-11
Abstract
Description
This article describes methods for treating cancers containing KRAS G12C mutations in subjects in need, including administering to the subject an effective therapeutic dose of sotorarazid, carboplatin, and pemetrexed. Abstract
Claims
What is claimed is:
1. A method of treating cancer comprising a KRAS G12C mutation in a subject in need thereof, the method comprising: administering to the subject (a) a first regimen comprising (i) a therapeutically effective amount of sotorasib, (ii) a therapeutically effective amount of carboplatin and (iii) a therapeutically effective amount of pemetrexed and then administering (b) a second regimen comprising (i) the therapeutically effective amount of sotorasib and (ii) the therapeutically effective amount of pemetrexed.
2. The method of claim 1 , wherein the first regimen is administered for a period of 4 cycles.
3. The method of claim 2, wherein each cycle is a period of 21 days.
4. The method of any one of claims 1 to 3, wherein the therapeutically effective amount of sotorasib is 240 mg.
5. The method of any one of claims 1 to 3, wherein the therapeutically effective amount of sotorasib is 960 mg.
6. The method of any one of claims 1 to 5, wherein the sotorasib is administered orally7. The method of any one of claims 1 to 6, wherein the sotorasib is administered once daily8. The method of any one of claims 1 to 7, wherein the sotorasib is administered as a solid dosage form.
9. The method of claim 8, wherein the solid dosage form is a tablet.
10. The method of claim 9, wherein the sotorasib is administered as one tablet comprising 240 mg of sotorasib, two tablets each comprising 120 mg of sotorasib, three tablets each comprising 320 mg of sotorasib, four tablets each comprising 240 mg of sotorasib, or eight tablets each comprising 120 mg of sotorasib.
11. The method of any one of claims 1 to 10, wherein the therapeutically effective amount of carboplatin is an amount corresponding to 5 mg / (mL x min) (AUC 5) multiplied with the subject’s glomerular filtration rate (GFR) in mL / min increased by 25 mL / min.
12. The method of claim 11, wherein the therapeutically effective amount of carboplatin is 750 mg or less.
13. The method of any one of claims 1 to 12, wherein the carboplatin is administered intravenously14. The method of any one of claims 2 to 13, wherein the carboplatin is administered on day 1 of each cycle.
15. The method of any one of claims 1 to 14, wherein the subject is not administered carboplatin during the second regimen.
16. The method of any one of claims 1 to 15, wherein the therapeutically effective amount of pemetrexed is 500 mg / m2.
17. The method of any one of claims 1 to 16, wherein pemetrexed is administered intravenously.
18. The method of any one of claims 1 to 17, wherein the administration of pemetrexed starts on day 1 of the first regimen19. The method of any one of claims 1 to 18, wherein the pemetrexed is administered in 21 day intervals during the first regimen and the second regimen.
20. The method of any one of claims 1 to 19, further comprising administering to the subject a therapeutically effective amount of folic acid.
21. The method of claim 20, wherein the therapeutically effective amount of folic acid is 350 pig to 1000 pig once daily.
22. The method of claim 20, wherein the therapeutically effective amount of folic acid is 400 pig once daily.
23. The method of claim 20, wherein the therapeutically effective amount of folic acid is 400 pig to 1000 pig once daily.
24. The method of claim 20 or claim 23, wherein the folic acid administration commences 7 days prior to pemetrexed administration and ends 21 days after cessation of pemetrexed administration.
25. The method of any one of claims 1 to 24, further comprising administering to the subject a therapeutically effective amount of vitamin B12.
26. The method of claim 25, wherein the therapeutically effective amount of vitamin B12 is 1 mg.
27. The method of claim 25 or claim 26, wherein the vitamin B12 is administered in the week prior to first pemetrexed administration and once every 9 weeks (± 2 weeks) thereafter until cessation of pemetrexed administration.
28. The method of claim 25 or claim 26, wherein the vitamin B12 is administered one week prior to first pemetrexed administration and once every 9 weeks thereafter until cessation of pemetrexed administration.
29. The method of any one of claims 25 to 28, wherein the vitamin B12 is administered intramuscularly.
30. The method of any one of claims 1 to 29, further comprising administering to the subject a therapeutically effective amount of dexamethasone.
31. The method of claim 30, wherein the therapeutically effective amount of dexamethasone is 4 mg twice daily.
32. The method of claim 30 or claim 31, wherein the dexamethasone is administered the day before, the day of, and the day after each pemetrexed administration to the subject.
33. The method of any one of claims 1 to 32, wherein the subject is an adult34. The method of any one of claims 1 to 33, wherein the subject, prior to treatment, has not received a prior systemic anticancer therapy for the cancer (first line treatment).
35. The method of any one of claims 1 to 34, wherein the subject has a creatinine clearance (CrC I) of equal or greater than 45 mL / min as calculated by the Cockcroft-Gault formula.
36. The method of any one of claims 1 to 35, wherein the subject has an ECOG Performance Status of 0 or 1.
37. The method of any one of claims 1 to 36, wherein the cancer exhibits a TC score of less than 1%.
38. The method of claim 37, wherein the therapeutically effective amount of sotorasib is 960 mg.
39. The method of claim 37, wherein the TC score was determined using the Ventana PD-L1 (SP263) IHC assay.
40. The method of any one of claims 1 to 36, wherein the cancer exhibits a PD-L1 tumor proportion score (TPS) of less than 1%.
41. The method of claim 40, wherein the therapeutically effective amount of sotorasib is 960 mg.
42. The method of claim 40, wherein the TPS was determined using the PD-L1 IHC 22C3 pharmDx assay.
43. The method of any one of claims 1 to 42, wherein the cancer does not comprise an EGFR or ALK alteration.
44. The method of any one of claims 1 to 43, wherein the cancer is lung cancer.
45. The method of any one of claims 1 to 43, wherein the cancer is non-small cell lung cancer.
46. The method of any one of claims 1 to 43, wherein the cancer is nonsquamous non-small cell lung cancer.
47. The method of claim 46, wherein the nonsquamous non-small cell lung cancer is stage IV or advanced stage IIIB / C.
48. The method of any one of claims 1 to 47, wherein the patient is not concomitantly administered an antibody.
49. The method of claim 48, wherein the antibody is an anti-VEGF antibody.
50. The method of claim 49, the anti-VEGF antibody is bevacizumab.
